Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

A double-blind, randomized trial of pyridoxine versus placebo for the prevention of pegylated liposomal doxorubicin-related hand-foot syndrome in gynecologic oncology patients.

von Gruenigen V, Frasure H, Fusco N, DeBernardo R, Eldermire E, Eaton S, Waggoner S.

Cancer. 2010 Oct 15;116(20):4735-43. doi: 10.1002/cncr.25262.

2.

Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of experts.

von Moos R, Thuerlimann BJ, Aapro M, Rayson D, Harrold K, Sehouli J, Scotte F, Lorusso D, Dummer R, Lacouture ME, Lademann J, Hauschild A.

Eur J Cancer. 2008 Apr;44(6):781-90. doi: 10.1016/j.ejca.2008.01.028. Epub 2008 Mar 10.

PMID:
18331788
3.

Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: results of a randomized, double-blind, placebo-controlled study.

Kang YK, Lee SS, Yoon DH, Lee SY, Chun YJ, Kim MS, Ryu MH, Chang HM, Lee JL, Kim TW.

J Clin Oncol. 2010 Aug 20;28(24):3824-9. doi: 10.1200/JCO.2010.29.1807. Epub 2010 Jul 12.

PMID:
20625131
4.

Predisposing risk factors for palmar-plantar erythrodysesthesia when using liposomal doxorubicin to treat recurrent ovarian cancer.

Tanyi JL, Smith JA, Ramos L, Parker CL, Munsell MF, Wolf JK.

Gynecol Oncol. 2009 Aug;114(2):219-24. doi: 10.1016/j.ygyno.2009.04.007. Epub 2009 May 17.

PMID:
19446868
5.

Treatment of recurrent platinum-resistant ovarian cancer with pegylated liposomal doxorubicin--an evaluation of the therapeutic index with special emphasis on cardiac toxicity.

Steppan I, Reimer D, Sevelda U, Ulmer H, Marth C, Zeimet AG.

Chemotherapy. 2009;55(6):391-8. doi: 10.1159/000262452. Epub 2009 Nov 30.

PMID:
19955744
6.

Prevention strategies in palmar-plantar erythrodysesthesia onset: the role of regional cooling.

Mangili G, Petrone M, Gentile C, De Marzi P, Viganò R, Rabaiotti E.

Gynecol Oncol. 2008 Feb;108(2):332-5.

PMID:
18083217
7.

Impact of prophylactic pyridoxine on occurrence of hand-foot syndrome in patients receiving capecitabine for advanced or metastatic breast cancer.

Yoshimoto N, Yamashita T, Fujita T, Hayashi H, Tsunoda N, Kimura M, Tsuzuki N, Yamashita H, Toyama T, Kondo N, Iwata H.

Breast Cancer. 2010 Oct;17(4):298-302. doi: 10.1007/s12282-009-0171-3. Epub 2009 Sep 30.

PMID:
19789949
8.

Phase II clinical trial of pegylated liposomal doxorubicin (JNS002) in Japanese patients with mullerian carcinoma (epithelial ovarian carcinoma, primary carcinoma of fallopian tube, peritoneal carcinoma) having a therapeutic history of platinum-based chemotherapy: a Phase II Study of the Japanese Gynecologic Oncology Group.

Katsumata N, Fujiwara Y, Kamura T, Nakanishi T, Hatae M, Aoki D, Tanaka K, Tsuda H, Kamiura S, Takehara K, Sugiyama T, Kigawa J, Fujiwara K, Ochiai K, Ishida R, Inagaki M, Noda K.

Jpn J Clin Oncol. 2008 Nov;38(11):777-85. doi: 10.1093/jjco/hyn101. Epub 2008 Oct 16.

9.

Combination therapy with pegylated liposomal doxorubicin and carboplatin in gynecologic malignancies: a prospective phase II study of the Arbeitsgemeinschaft Gynäekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and Kommission Uterus (AGO-K-Ut).

du Bois A, Pfisterer J, Burchardi N, Loibl S, Huober J, Wimberger P, Burges A, Stähle A, Jackisch C, Kölbl H; Arbeitsgemeinschaft Gynäekologische Onkologie Studiengruppe Ovarialkarzinom; Kommission Uterus.

Gynecol Oncol. 2007 Dec;107(3):518-25. Epub 2007 Oct 25.

PMID:
17910981
10.

Elevated body mass index does not increase the risk of palmar-plantar erythrodysesthesia in patients receiving pegylated liposomal doxorubicin.

Gordinier ME, Dizon DS, Fleming EL, Weitzen S, Schwartz J, Parker LP, Granai CO.

Gynecol Oncol. 2006 Oct;103(1):72-4. Epub 2006 Feb 21.

PMID:
16494932
11.

A multicentre phase II study of carboplatin plus pegylated liposomal doxorubicin as first-line chemotherapy for patients with advanced or recurrent endometrial carcinoma: the END-1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) group.

Pignata S, Scambia G, Pisano C, Breda E, Di Maio M, Greggi S, Ferrandina G, Lorusso D, Zagonel V, Febbraro A, Riva N, De Rosa V, Gallo C, Perrone F; Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies Group.

Br J Cancer. 2007 Jun 4;96(11):1639-43. Epub 2007 May 8.

12.

Pegylated liposomal doxorubicin treatment in recurrent gynecologic cancer patients with renal dysfunction.

Li Y, Finkel KW, Hu W, Fu S, Liu J, Coleman R, Kavanagh JJ.

Gynecol Oncol. 2007 Aug;106(2):375-80. Epub 2007 May 18.

PMID:
17512575
13.

Maintenance treatment with pegylated liposomal doxorubicin versus observation following induction chemotherapy for metastatic breast cancer: GEICAM 2001-01 study.

Alba E, Ruiz-Borrego M, Margelí M, Rodríguez-Lescure A, Sánchez-Rovira P, Ruiz A, Mel-Lorenzo JR, Ramos-Vázquez M, Ribelles N, Calvo E, Casado A, Márquez A, Vicente D, García-Sáenz JA, Martín M.

Breast Cancer Res Treat. 2010 Jul;122(1):169-76. doi: 10.1007/s10549-010-0860-9. Epub 2010 Apr 2.

PMID:
20361253
14.

A phase-I study evaluating the combination of pegylated liposomal doxorubicin and paclitaxel as salvage chemotherapy in metastatic breast cancer previously treated with anthracycline.

Hong RL, Lin CH, Chao TY, Kao WY, Wang CH, Hsieh RK, Hwang WS.

Cancer Chemother Pharmacol. 2008 Apr;61(5):847-53. Epub 2007 Jul 4.

PMID:
17609947
15.

Skin problems associated with pegylated liposomal doxorubicin-more than palmoplantar erythrodysesthesia syndrome.

Mangana J, Zipser MC, Conrad C, Oberholzer PA, Cozzio A, Knuth A, French LE, Dummer R.

Eur J Dermatol. 2008 Sep-Oct;18(5):566-70. doi: 10.1684/ejd.2008.0490. Epub 2008 Aug 8.

17.

Phase I clinical trial of topotecan and pegylated liposomal doxorubicin.

Garcia AA, Roman L, Muderspach L, O'meara A, Facio G, Edwards S, Burnett A.

Cancer Invest. 2005;23(8):665-70.

PMID:
16377584
18.

Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum.

Markman M, Kennedy A, Webster K, Peterson G, Kulp B, Belinson J.

Gynecol Oncol. 2000 Sep;78(3 Pt 1):369-72.

PMID:
10985896
19.

Pyridoxine as prophylactic therapy for palmar-plantar erythrodysesthesia associated with administration of pegylated liposomal doxorubicin (caelyx): a single-center experience.

Rossi D, Catalano G.

Oncology. 2007;73(3-4):277-8. doi: 10.1159/000127427. Epub 2008 Apr 17. No abstract available.

PMID:
18424894
20.

Phase II trial of biweekly pegylated liposomal doxorubicin in recurrent platinum-refractory ovarian and peritoneal cancer.

Strauss HG, Hemsen A, Karbe I, Lautenschläger C, Persing M, Thomssen C.

Anticancer Drugs. 2008 Jun;19(5):541-5. doi: 10.1097/CAD.0b013e3282fcbbf7.

PMID:
18418221

Supplemental Content

Support Center